Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb:61:77-83.
doi: 10.1016/j.breast.2021.12.006. Epub 2021 Dec 13.

The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis

Hee Jeong Kim  1 , Seonok Kim  2 , Rachel A Freedman  3 , Ann H Partridge  4
Affiliations

The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis

Hee Jeong Kim et al. Breast. 2022 Feb.

Abstract

Purpose: Women under 40 years old are at increased risk for developing human epidermal growth factor receptor 2 (HER2) positive or triple negative subtype and more advanced breast cancer, yet young age itself has also historically been an independent prognostic factor.

Methods: Using the Surveillance, Epidemiology, and End Results (SEER) Program, we examined data for 271,173 women with stage I-III breast cancer between 2010 and 2015. Using Fine and Gray regression models to account for competing risks, we examined the risk of breast cancer-specific death by age and clinical subtypes, considering grade, hormone receptor (HR) and HER2 status, adjusting for demographic, clinical and treatment variables.

Results: Of 271,173 women eligible for analysis, 14,109 were <40 years of age. Women under 40 years old were more likely to be non-white, uninsured, and to have higher stage, higher grade, HER2-positive and triple-negative subtype disease (all, p < 0.001). Compared to women ages 40-60, women ages <40 had higher breast cancer mortality (hazard ratio, 1.8; 95% confidence interval (CI) 1.6-1.9) in unadjusted analysis. In models controlling for demographic, clinical and treatment factors, young age was significantly associated with an increased risk of breast cancer mortality among women with HR-positive, lower grade disease (hazard ratio 1.7; 95% CI 1.4-2.1) but not for women with high grade/HR-positive, HER2-positive, or triple-negative disease. Women age >75 had increased breast cancer mortality in all subtypes.

Conclusion: With modern clinical subtyping, age under 40 remains independently associated with worse outcomes in 30 months follow-up only in HR-positive, lower grade disease.

Keywords: Age; Breast cancer; Outcomes; Subtype; Young women.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None.

Figures

Fig. 1
Fig. 1
Flow scheme of the Study.
Fig. 2
Fig. 2
Cumulative incidence functions for cancer specific death according to age group in: A) all patients, B) HR positive, lower grade, C) HR positive, high grade/HR positive, HER2 positive, D) HER2 positive, E) Triple negative from SEER data.
See this image and copyright information in PMC

References

    1. Guo F., Kuo Y.F., Shih Y.C.T., Giordano S.H., Berenson A.B. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. Sep 1 2018;124(17):3500–3509. doi: 10.1002/cncr.31638. - DOI - PMC - PubMed
    1. Partridge A.H., Gelber S., Piccart-Gebhart M.J., et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol: official journal of the American Society of Clinical Oncology. Jul 20 2013;31(21):2692–2698. doi: 10.1200/jco.2012.44.1956. - DOI - PubMed
    1. Adami H.O., Malker B., Holmberg L., Persson I., Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. Aug 28 1986;315(9):559–563. doi: 10.1056/nejm198608283150906. - DOI - PubMed
    1. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. Dec 29 1988;319(26):1681–1692. doi: 10.1056/nejm198812293192601. - DOI - PubMed
    1. Sainsbury R. The development of endocrine therapy for women with breast cancer. Cancer Treat Rev. Aug 2013;39(5):507–517. doi: 10.1016/j.ctrv.2012.07.006. - DOI - PubMed